Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 14/20 | 1.00 |
| ▸ | KCNJ11 | Q14654 | 14/20 | 1.00 |
| ▸ | ABCC8 | Q09428 | 8/20 | 1.00 |
| ▸ | KCNJ8 | Q15842 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2129489 | 1.00 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL12648389 | 1.00 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL11162954 | 0.89 | ABCC9 (0.80) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL6369800 | 0.87 | ABCC9 (0.77) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL11166863 | 0.87 | ABCC9 (0.77) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL11157791 | 0.82 | ABCC9 (0.70) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL8774811 | 0.81 | ABCC9 (0.69) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL8747789 | 0.78 | KMT2A (0.63) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL9456841 | 0.78 | ABCC9 (0.73) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL3701757 | 0.77 | ABCC9 (0.63) | ABCC9KCNJ11ABCC8KCNJ8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142124-A1 | Compositions for Topical Application Having Androgenic Actions | AVENTIS PHARMA SA (DE) | 2014-05-22 | — | — | US | claimed |
| US-20120100229-A1 | Treatment and Prevention of White Matter Injury with KATP Channel Activators | YALE UNIVERSITY | 2012-04-26 | — | — | US | claimed |
| WO-2010111518-A1 | TREATMENT AND PREVENTION OF WHITE MATTER INJURY WITH KATP CHANNEL ACTIVATORS | YALE UNIVERSITY (US) | 2010-09-30 | — | — | WO | claimed |
| EP-1123082-B1 | PREPARATIONS FOR TOPICAL APPLICATION OF SUBSTANCES HAVING ANTIANDROGENIC EFFECT | AVENTIS PHARMA SA (FR) | 2006-03-01 | — | — | EP | claimed |
| US-20030083322-A1 | COMPOSITIONS FOR TOPICAL APPLICATION HAVING ANDREGENIC ACTIONS | AVENTIS PHARMA S.A. (FR) | 2003-05-01 | — | — | US | claimed |
| EP-1123082-A1 | PREPARATIONS FOR TOPICAL APPLICATION OF SUBSTANCES HAVING ANTIANDROGENIC EFFECT | Aventis Pharma Deutschland GmbH (DE) | 2001-08-16 | — | — | EP | claimed |
| WO-2000024366-A1 | PREPARATIONS FOR TOPICAL APPLICATION OF SUBSTANCES HAVING ANTIANDROGENIC EFFECT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-05-04 | — | — | WO | claimed |
| US-20140142124-A1 | Compositions for Topical Application Having Androgenic Actions | AVENTIS PHARMA SA (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20120100229-A1 | Treatment and Prevention of White Matter Injury with KATP Channel Activators | YALE UNIVERSITY | 2012-04-26 | — | — | US | disclosed |
| US-20110065763-A1 | Compositions for Topical Application Having Androgenic Actions | AVENTIS PHARMA S.A | 2011-03-17 | — | — | US | disclosed |
| WO-2010111518-A1 | TREATMENT AND PREVENTION OF WHITE MATTER INJURY WITH KATP CHANNEL ACTIVATORS | YALE UNIVERSITY (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20090093487-A1 | Compositions for topical application having androgenic actions | AVENTIS PHARMA S.A. | 2009-04-09 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-6875438-B2 | Preparations for topical administration of substances having antiandrogenic activity | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-05 | — | — | US | disclosed |
| EP-1501806-A1 | PREPARATIONS FOR THE TOPICAL APPLICATION OF ANTI-ANDROGENICALLY ACTIVE SUBSTANCES | Aventis Pharma Deutschland GmbH (DE) | 2005-02-02 | — | — | EP | disclosed |
| US-20030229129-A1 | Preparations for topical administration of substances having antiandrogenic activity | AVENTIS PHARMA S.A. (FR) | 2003-12-11 | — | — | US | disclosed |
| WO-2003093243-A1 | PREPARATIONS FOR THE TOPICAL APPLICATION OF ANTI-ANDROGENICALLY ACTIVE SUBSTANCES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | WO | disclosed |
| US-20030083322-A1 | COMPOSITIONS FOR TOPICAL APPLICATION HAVING ANDREGENIC ACTIONS | AVENTIS PHARMA S.A. (FR) | 2003-05-01 | — | — | US | disclosed |
| EP-1123082-A1 | PREPARATIONS FOR TOPICAL APPLICATION OF SUBSTANCES HAVING ANTIANDROGENIC EFFECT | Aventis Pharma Deutschland GmbH (DE) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000024366-A1 | PREPARATIONS FOR TOPICAL APPLICATION OF SUBSTANCES HAVING ANTIANDROGENIC EFFECT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ABCC9 384/4885KCNJ11 18/4885ABCC8 415/4885 |
| US-20030083322-A1 | COMPOSITIONS FOR TOPICAL APPLICATION HAVING ANDREGENIC ACTIONS | NR5A1, CYP17A1, CYP19A1 | ABCC9 4551/4885KCNJ11 2385/4885ABCC8 4251/4885 |
| US-20030229129-A1 | Preparations for topical administration of substances having antiandrogenic activity | NR5A1, CYP17A1, HSD17B11 | ABCC9 2570/4885KCNJ11 2301/4885ABCC8 1810/4885 |
| US-20090093487-A1 | Compositions for topical application having androgenic actions | NR5A1, CYP17A1, CYP19A1 | ABCC9 4555/4885KCNJ11 3184/4885ABCC8 3942/4885 |
| US-20140142124-A1 | Compositions for Topical Application Having Androgenic Actions | NR5A1, CYP17A1, CYP19A1 | ABCC9 4555/4885KCNJ11 3184/4885ABCC8 3942/4885 |
| US-20110065763-A1 | Compositions for Topical Application Having Androgenic Actions | NR5A1, CYP17A1, CYP19A1 | ABCC9 4555/4885KCNJ11 3184/4885ABCC8 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.